QinetiQ Ltd. provides technical, engineering, and research services for defense and security problems. It offers products and services for air, cyber, maritime, robotics, space, land, training, weapons, advisory systems, and target systems. The company was founded in June 2001 and is headquartered in Farnborough, the United Kingdom.

Ramot at Tel Aviv University Ltd. operates as a technology transfer company of Tel Aviv University (TAU). It provides legal and commercial frameworks for inventions made by TAU faculty, students, and researchers. The firm licenses the university's intellectual property to third parties through agreements; facilitates collaborative research partnerships between business partners and TAU researchers; establishes a company; and forms joint ventures that promote TAU technologies. The company was founded in 1973 and is headquartered in Tel Aviv, Israel.

Ra Pharma is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma is leveraging its ability to rapidly generate drug candidates to develop its own portfolio of products and partnerships focused on intracellular protein-protein interactions and other innovative approaches to addressing unmet medical needs. It was founded in 2008 and headquartered in Cambridge, Massachusetts.

B·R·A·H·M·S explores, develops and produces new diagnostic test procedures to improve the diagnosis, and thereby the treatment, of life-threatening illnesses. This takes place with over 400 employees, on the basis of their own patented biomarkers, and leads to medically and economically superior diagnostic insights for patients and medical professionals. B·R·A·H·M·S products reach customers in over 65 countries around the world and are leaders in their specialized markets.

Signal Pharmaceuticals is a biopharmaceutical company that was founded by David Anderson (Senior VP & Head of Research), Alan Lewis (CEO), Mark Carmen, and Jackie Johnson and is based in California. It was acquired by Celgene in 2009

Nestec SA, a subsidiary of Nestlé SA, is a Swiss company located in Vevey. The firm manufactures nutrition food products.

Ordway Research Institute I

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

LocomoGene, Inc. is a Japanese private company located in Yokohama that develops novel medicines based on genome research.

Sekisui Medical Co., Ltd., part of Sekisui Chemical Co., Ltd., is a company headquartered in Tokyo, Japan, that manufactures and markets in-vitro diagnostic substances and pharmaceutical products. Sekisui Chemical Co., Ltd. acquired Sekisui Medical Co., Ltd. from Daiichi Sankyo Co., Ltd. on October 02, 2006.

Since 1985, Atto Bioscience (formerly Atto Instruments) has provided innovative solutions to pharmaceutical, academic, and research groups in cellular biology. Combining the proven expertise of its top scientists with its unique, flexible, and easily-integrated technology, Atto redefines cellular research and drug discovery with customized and innovative approaches that enhance any research process. Atto’s key competitive advantage is the ability to integrate biology, imaging instrumentation, engineering, and manufacturing and to deliver to the life science, pharmaceutical and toxicology community a comprehensive offering of assays, instrumentation and services. Their in-house design and development of technology affords us a better understanding of application areas allowing us to adapt to the demands of their customers, and to quickly engineer and develop state-of-the-art imaging solutions to meet those demands. In the summer of 2001, Atto reorganized to expand into the drug discovery market place. As part of the reorganization Atto expanded their management and business teams and has doubled the size of the company over the last year. Atto also strengthened its scientific teams by bringing in some of the lead scientists in cell and molecular biology also from Life Technologies. These new personnel additions along with new venture money have allowed Atto to aggressively move into the high-throughput cell imaging marketplace. From secondary screening techniques to pre-clinical research, Atto technologies and expertise creates improved strategies for reducing time and increasing downstream success.

Spectral Platforms develops tools for the rapid diagnosis of infectious diseases in clinical samples. Its tools can characterize pathogen presence in 5 minutes (compared to current methods that take 24 hours), and characterize antimicrobial susceptibility/resistance information in 40 minutes (compared to current methods that take 48 hours). The company was founded in 2011 and is headquartered in Monrovia, California.

The Japanese Cancer Research Foundation supports the establishment of a cancer institute and its affiliated hospital. It has been leading the research and treatment of cancer thru activities integrating basic and clinical research. It shows their accomplishments in cancer research and treatment over a long history. It is one of the the world-s institutes in bioscience. They are making accomplishments in the treatment of cancer its related diseases with efficient medical staff and leading-edge medical equipment.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.